Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology.

Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology.
复制标题

基于cell-SELEX技术的核酸适配体在结直肠癌诊治中的应用

DOI:
10.1038/s41698-017-0041-y
复制
发表时间:
2017
影响因子:
7.9
通讯作者:
Tang F
Tang F
中科院分区:
医学1区
文献类型:
--
作者:
Chen C;Zhou S;Cai Y;Tang F

文献摘要

参考文献

被引文献

相似文献

核酸适体是一类高亲和力的核酸配体。由于它们的高亲和力和特异性,它们充当“化学抗体”。核酸适体是使用通过指数富集的配体系统进化(SELEX)技术从核酸随机序列产生的。SELEX是从不同靶标有效选择适体的过程。近年来发展起来的基于细胞的SELEX技术已广泛应用于生物标志物的发现、早期诊断和肿瘤靶向治疗,尤其是在结直肠癌(CRC)的治疗中。结合纳米结构,构建了纳米适体-药物传递系统。用适体官能化的各种纳米结构是高效的,并且已经用于CRC治疗应用中。本文介绍了细胞- SELEX技术,并综述了适体作为生物标志物在结直肠癌诊断和治疗中的潜在应用。阐述了适体靶向纳米载体在结直肠癌中的一些特点。本文还讨论了cell-SELEX的挑战和前景。
Nucleic acid aptamers are a class of high-affinity nucleic acid ligands. They serve as “chemical antibodies” since their high affinity and specificity. Nucleic acid aptamers are generated from nucleic acid random-sequence using a systematic evolution of ligands by exponential enrichment (SELEX) technology. SELEX is a process of effectively selecting aptamers from different targets. A newly developed cell-based SELEX technique has been widely used in biomarker discovery, early diagnosis and targeted cancer therapy, particular at colorectal cancer (CRC). Combined with nanostructures, nano-aptamer-drug delivery system was constructed for drug delivery. Various nanostructures functionalized with aptamers are highly efficient and has been used in CRC therapeutic applications. In the present, we introduce a cell- SELEX technique, and summarize the potential application of aptamers as biomarkers in CRC diagnosis and therapy. And some characteristics of aptamer-targeted nanocarriers in CRC have been expatiated. The challenges and perspectives for cell-SELEX are also discussed.
DOI: 10.1007/s10753-015-0258-2
发表时间: 2016-02-01
期刊: INFLAMMATION
影响因子: 5.1
作者:
Ahn, Chang-Bum;Jung, Won-Kyo;Je, Jae-Young
通讯作者: Je, Jae-Young
DOI: 10.1093/nar/gkn967
发表时间: 2009-02
影响因子: 14.9
作者:
Ferreira CS;Cheung MC;Missailidis S;Bisland S;Gariépy J
通讯作者: Gariépy J
DOI: 10.3390/ph9020029
发表时间: 2016-05-19
期刊: Pharmaceuticals (Basel, Switzerland)
影响因子: --
作者:
Gijs M;Penner G;Blackler GB;Impens NR;Baatout S;Luxen A;Aerts AM
通讯作者: Aerts AM
DOI: 10.1016/j.talanta.2016.07.018
发表时间: 2017-03-01
期刊: TALANTA
影响因子: 6.1
作者:
Cao, Hongmei;Fang, Xueen;Kong, Jilie
通讯作者: Kong, Jilie
DOI: 10.1074/jbc.m111.238261
发表时间: 2011-06-17
影响因子: 4.8
作者:
Boltz, Achim;Piater, Birgit;Hock, Bjoern
通讯作者: Hock, Bjoern